Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Lurasidone inhibits NMDA receptor antagonist-induced functional abnormality of thalamocortical glutamatergic transmission via 5-HT 7 receptor blockade.

Tytuł:
Lurasidone inhibits NMDA receptor antagonist-induced functional abnormality of thalamocortical glutamatergic transmission via 5-HT 7 receptor blockade.
Autorzy:
Okada M; Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu, Japan.
Fukuyama K; Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu, Japan.
Ueda Y; Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu, Japan.
Źródło:
British journal of pharmacology [Br J Pharmacol] 2019 Oct; Vol. 176 (20), pp. 4002-4018. Date of Electronic Publication: 2019 Sep 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: London : Wiley
Original Publication: London, Macmillian Journals Ltd.
MeSH Terms:
Antipsychotic Agents/*pharmacology
Dizocilpine Maleate/*antagonists & inhibitors
Lurasidone Hydrochloride/*pharmacology
Receptors, N-Methyl-D-Aspartate/*antagonists & inhibitors
Receptors, Serotonin/*metabolism
Serotonin Antagonists/*pharmacology
Animals ; Antipsychotic Agents/administration & dosage ; Dizocilpine Maleate/pharmacology ; Glutamic Acid/drug effects ; Glutamic Acid/metabolism ; Lurasidone Hydrochloride/administration & dosage ; Male ; Mediodorsal Thalamic Nucleus/drug effects ; Perfusion ; Rats ; Rats, Sprague-Dawley ; Receptors, N-Methyl-D-Aspartate/metabolism ; Serotonin Antagonists/administration & dosage ; Synaptic Transmission/drug effects ; Thalamus/drug effects ; Thalamus/metabolism
References:
Psychopharmacology (Berl). 2018 Oct;235(10):2795-2808. (PMID: 30066135)
Expert Opin Drug Saf. 2018 Feb;17(2):197-205. (PMID: 28902525)
J Comp Neurol. 1992 May 8;319(2):299-311. (PMID: 1381728)
J Med Chem. 1990 May;33(5):1296-305. (PMID: 1691788)
Br J Pharmacol. 2009 Jun;157(4):656-65. (PMID: 19371334)
Pharmacol Rev. 2008 Sep;60(3):358-403. (PMID: 18922967)
Br J Pharmacol. 2018 Apr;175(7):987-993. (PMID: 29520785)
J Neurosci. 2017 Nov 1;37(44):10529-10540. (PMID: 29093055)
Eur J Pharmacol. 2011 Feb 25;653(1-3):47-57. (PMID: 21147094)
Neuropsychopharmacology. 2007 Aug;32(8):1840-54. (PMID: 17203014)
J Neurochem. 2014 Mar;128(6):938-49. (PMID: 24164459)
Int J Mol Sci. 2018 Nov 19;19(11):. (PMID: 30463253)
Behav Brain Res. 2013 May 1;244:66-9. (PMID: 23376699)
Schizophr Res. 2010 Nov;123(2-3):93-104. (PMID: 20832997)
Neurosci Biobehav Rev. 2015 Jul;54:89-107. (PMID: 25616182)
Neuroscience. 2004;124(4):901-11. (PMID: 15026130)
Trends Neurosci. 2008 May;31(5):234-42. (PMID: 18395805)
Hillside J Clin Psychiatry. 1987;9(1):12-35. (PMID: 2820854)
Br J Pharmacol. 2012 Mar;165(5):1543-55. (PMID: 21880034)
Neuroscience. 2005;134(1):233-46. (PMID: 15961239)
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. (PMID: 29149325)
Cereb Cortex. 1994 Jan-Feb;4(1):69-77. (PMID: 8180492)
Neurosci Lett. 1986 Dec 23;72(3):330-4. (PMID: 3822236)
Pharmacol Res Perspect. 2019 Feb;7(1):e00457. (PMID: 30784207)
Nat Rev Neurosci. 2007 Jul;8(7):536-46. (PMID: 17585306)
Behav Brain Res. 2011 Jun 20;220(1):83-90. (PMID: 21277905)
PLoS One. 2011;6(6):e20210. (PMID: 21701689)
J Neurochem. 2001 Mar;76(5):1521-31. (PMID: 11238736)
Br J Pharmacol. 2013 Mar;168(5):1088-100. (PMID: 22882023)
Br J Pharmacol. 2010 Aug;160(7):1577-9. (PMID: 20649561)
Br J Pharmacol. 2017 Dec;174 Suppl 1:S130-S159. (PMID: 29055038)
Br J Pharmacol. 2019 Oct;176(20):4002-4018. (PMID: 31347694)
J Neurosci. 1997 Apr 15;17(8):2921-7. (PMID: 9092613)
Neuropharmacology. 2019 Sep 15;156:107547. (PMID: 30802458)
Neuropharmacology. 2012 Feb;62(2):765-74. (PMID: 21925189)
Synapse. 2011 Sep;65(9):919-28. (PMID: 21308802)
Int J Neuropsychopharmacol. 2013 Nov;16(10):2181-94. (PMID: 24099265)
Science. 1998 Aug 28;281(5381):1349-52. (PMID: 9721099)
Pharmacol Biochem Behav. 2017 Jun;157:16-23. (PMID: 28455126)
J Neurophysiol. 2002 Apr;87(4):2124-36. (PMID: 11929930)
Prog Brain Res. 2008;172:177-97. (PMID: 18772033)
Br J Pharmacol. 2010 Aug;160(7):1573-6. (PMID: 20649560)
J Pharmacol Exp Ther. 2010 Jul;334(1):171-81. (PMID: 20404009)
Prog Neurobiol. 1998 Mar;54(4):417-58. (PMID: 9522395)
Handb Exp Pharmacol. 2012;(212):87-124. (PMID: 23129329)
Mol Pharmacol. 2012 Feb;81(2):113-9. (PMID: 22072817)
Hum Psychopharmacol. 2013 Sep;28(5):495-505. (PMID: 24014143)
Eur J Neurosci. 2007 May;25(10):2991-3000. (PMID: 17561813)
Biomolecules. 2019 May 17;9(5):. (PMID: 31108896)
Neuroimage. 2002 Mar;15(3):620-32. (PMID: 11848705)
J Physiol. 1991 Oct;442:235-55. (PMID: 1665858)
Br J Pharmacol. 2017 Dec;174 Suppl 1:S17-S129. (PMID: 29055040)
Front Syst Neurosci. 2016 Dec 27;10:104. (PMID: 28082874)
Curr Biol. 2017 Jun 19;27(12):R580-R586. (PMID: 28633023)
Trends Neurosci. 2017 Apr;40(4):200-207. (PMID: 28314446)
Neuroscience. 2003;117(3):697-706. (PMID: 12617973)
Neuroimage. 2009 May 15;46(1):31-8. (PMID: 19457373)
Front Cell Neurosci. 2015 Aug 18;9:324. (PMID: 26347612)
J Pharmacol Exp Ther. 2011 Aug;338(2):605-14. (PMID: 21558435)
Psychopharmacology (Berl). 2009 Oct;206(2):243-58. (PMID: 19575183)
Trends Pharmacol Sci. 2009 Jan;30(1):25-31. (PMID: 19058862)
Neuropsychopharmacology. 1996 May;14(5):301-7. (PMID: 8703299)
Mol Brain. 2013 May 14;6:24. (PMID: 23672716)
Substance Nomenclature:
0 (Antipsychotic Agents)
0 (Receptors, N-Methyl-D-Aspartate)
0 (Receptors, Serotonin)
0 (Serotonin Antagonists)
0 (serotonin 7 receptor)
3KX376GY7L (Glutamic Acid)
6LR8C1B66Q (Dizocilpine Maleate)
O0P4I5851I (Lurasidone Hydrochloride)
Entry Date(s):
Date Created: 20190727 Date Completed: 20200922 Latest Revision: 20230106
Update Code:
20240105
PubMed Central ID:
PMC6811777
DOI:
10.1111/bph.14804
PMID:
31347694
Czasopismo naukowe
Background and Purpose: Lurasidone is an atypical mood-stabilizing antipsychotic with a unique receptor-binding profile, including 5-HT 7 receptor antagonism; however, the detailed effects of 5-HT 7 receptor antagonism on various transmitter systems relevant to schizophrenia, particularly the thalamo-insular glutamatergic system and the underlying mechanisms, are yet to be clarified.
Experimental Approach: We examined the mechanisms underlying the clinical effects of lurasidone by measuring the release of l-glutamate, GABA, dopamine, and noradrenaline in the reticular thalamic nucleus (RTN), mediodorsal thalamic nucleus (MDTN) and insula of freely moving rats in response to systemic injection or local infusion of lurasidone or MK-801 using multiprobe microdialysis with ultra-HPLC.
Key Results: Systemic MK-801 (0.5 mg·kg -1 ) administration increased insular release of l-glutamate, dopamine, and noradrenaline but decreased GABA release. Systemic lurasidone (1 mg·kg -1 ) administration also increased insular release of l-glutamate, dopamine, and noradrenaline but without affecting GABA. Local lurasidone administration into the insula (3 μM) did not affect MK-801-induced insular release of l-glutamate or catecholamine, whereas local lurasidone administration into the MDTN (1 μM) inhibited MK-801-induced insular release of l-glutamate and catecholamine, similar to the 5-HT 7 receptor antagonist SB269970.
Conclusions and Implications: The present results indicate that MK-801-induced insular l-glutamate release is generated by activation of thalamo-insular glutamatergic transmission via MDTN GABAergic disinhibition resulting from NMDA receptor inhibition in the MDTN and RTN. Lurasidone inhibited this MK-801-evoked insular l-glutamate release through inhibition of excitatory 5-HT 7 receptor in the MDTN. These effects on thalamo-insular glutamatergic transmission may contribute to the antipsychotic and mood-stabilizing actions of lurasidone.
(© 2019 The British Pharmacological Society.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies